Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

36.05
-0.3900-1.07%
Post-market: 36.900.8500+2.36%16:55 EDT
Volume:5.78M
Turnover:207.96M
Market Cap:42.00B
PE:60.08
High:36.33
Open:36.17
Low:35.62
Close:36.44
52wk High:38.37
52wk Low:18.14
Shares:1.17B
Float Shares:1.09B
Volume Ratio:1.36
T/O Rate:0.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):1.21
ROE:9.69%
ROA:5.13%
PB:5.42
PE(LYR):29.79

Loading ...

Teva Pharmaceutical Industries Limited.. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 29

Teva Lifts Sales View as Brand-Name Business Gains Traction

Dow Jones
·
Jul 29

Stock Track | Teva Pharmaceutical Soars 5.15% in Pre-Market Trading on Q2 Revenue Beat and Guidance

Stock Track
·
Jul 29

Movement Alert|Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss

Market Focus
·
Jul 29

GUIDANCE: (TEVA) Teva Pharmaceutical Expects 2026 Revenue Range $16.5B - $16.85B

MT Newswires Live
·
Jul 29

Teva Pharmaceutical Indus Q2 Adj. EPS $0.02 Misses $0.25 Estimate, Sales $4.142B Beat $4.047B Estimate

Benzinga Earnings
·
Jul 29

Teva Stock is Rebounding. Its Drug Pipeline Holds the Key to Growth.

Dow Jones
·
Jul 29

Teva Pharmaceuticals is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jul 28

Should Teva’s Branded-Drug Pivot and Duvakitug Bet Reshape How TEVA Investors View Earnings Power?

Simply Wall St.
·
Jul 28

Teva Pharmaceutical Industries Limited.. Expected to Post Earnings of 29 Cents a Share - Earnings Preview

Reuters
·
Jul 27

Why Teva Pharmaceutical Stock is a Buy Despite Trump Tariff Threat

Dow Jones
·
Jul 24

Earning Preview: Teva Pharmaceutical Q2 revenue is expected to decrease by 5.44%, and institutional views are mixed-bullish

Earnings Agent
·
Jul 22

What Teva Pharmaceutical Industries (TEVA)'s TEV‑408 Vitiligo Data and Funding Deal Means For Shareholders

Simply Wall St.
·
Jul 17

Colin Cieszynski’s Top Picks for July 15, 2026

Bloomberg
·
Jul 16

US Appeals Court Revives Teva Lawsuit over Lilly Osteoporosis Drug

Reuters
·
Jul 14

Jefferies Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)

TIPRANKS
·
Jul 10

Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live
·
Jul 09

Teva, Polpharma Biologics announce global licensing agreement

TIPRANKS
·
Jul 09

Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada

MT Newswires Live
·
Jul 09

Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ

TIPRANKS
·
Jul 09